Aflibercept for PCV: comparing treatment schedules
Part of Eyes & vision clinical trials.
This trial tests a new dose of aflibercept given on different schedules for people with PCV, a type of vision loss. It aims to see which schedule works best and how long the benefit lasts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 50 years old.
- You must have a confirmed diagnosis of active PCV in at least one eye, with current symptoms.
- Your vision in the study eye must be between 20/32 and 20/320 on an eye chart.
- You cannot have had any prior treatment for PCV, like anti-VEGF shots, laser, or PDT.
- You must not have uncontrolled high blood pressure (above 160/95) or other serious eye conditions that could affect results.
- You must agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
This trial tests a new treatment for people with a hard-to-treat form of wet age-related macular degeneration (AMD) that has not improved with standard anti-VEGF injections. It aims to stop the disease from getting worse and possibly improve vision.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This trial tests a higher dose of aflibercept given on a flexible schedule for people who have not yet been treated for wet age-related macular degeneration (nAMD). It aims to see if this approach is safe and effective at improving vision.
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
Hear when a new Polypoidal Choroidal Vasculopathy (PCV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.